Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid Arthritis

NCT03599986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 398

Last updated 2020-06-30

Study results available
· View outcomes & findings →

Summary

A Phase IV, Multi-Centric, Prospective, Observational Study to Assess the Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis. (CLEAR)

Conditions

  • Active Rheumatoid Arthritis

Sponsors & Collaborators

  • DataClin

    collaborator INDUSTRY
  • Eva Pharma

    lead INDUSTRY

Principal Investigators

  • Adel Elsayed, MD · Professor, Department of Internal Medicine, Rheumatology and Immunology, Ain Shams University; Egypt

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-16
Primary Completion
2018-10-13
Completion
2018-10-13

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03599986 on ClinicalTrials.gov